Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
7 Stocks With Impressive Earnings Growth: Real or Engineered?
06:45am, Wednesday, 19'th Jun 2024
Earnings are exactly what they sound like. They're everything that's left over after everything else has been paid.
3 Mega Cap Stock Bargains As Markets Hit All-Time Highs
02:51pm, Tuesday, 18'th Jun 2024
As markets continue to reach new all-time highs, investors are constantly seeking opportunities that offer both stability and growth potential. With the S&P 500 and Nasdaq recently hitting new all-tim
Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet
10:31am, Tuesday, 18'th Jun 2024
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employe
Bagsværd, Denmark, 18 June 2024 – Novo Nordisk today announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of the American Di
Novo Nordisk A/S - share repurchase programme
08:26am, Monday, 17'th Jun 2024
Bagsværd, Denmark, 17 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of
3 Best Stocks to Buy From the Fantastic 5
06:00am, Monday, 17'th Jun 2024
Wall Street loves coming up with cute little phrases, whether that be “FANG” or the more recent Magnificent 7. However, Thornburg portfolio manager Nicholas Anderson would like investors to be fam
3 Growth Stocks You Can Buy Right Now Without Any Hesitation
06:50am, Saturday, 15'th Jun 2024
Eli Lilly appears to be on course to become the first trillion-dollar healthcare stock. Novo Nordisk is one of the best ways to profit from the fast-growing obesity drug market.
Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors
06:50pm, Friday, 14'th Jun 2024
Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.
Novo Nordisk CEO to testify in US Senate hearing on high cost of Ozempic, Wegovy
05:41pm, Friday, 14'th Jun 2024
The Senate Committee on Health, Education, Labor, and Pensions said on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in a hearing focusing on U.S. prices for weight los
GLP-1 weight-loss drugs: Analyst discusses what investors should know
02:28pm, Friday, 14'th Jun 2024
GLP-1 weight-loss drugs have been major revenue generators for pharmaceutical companies such as Eli Lilly (LLY) and Novo Nordisk (NVO). Goldman Sachs US Lead Biotechnology Analyst Salveen Richter join
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
10:30am, Friday, 14'th Jun 2024
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
3 Stocks to Sell as Ozempic Surges in Popularity
06:37am, Friday, 14'th Jun 2024
Novo Nordisk's (NYSE: NVO ) Ozempic diabetes treatment, marketed as a weight loss treatment under the Wegovy brand name, has become the latest mega-blockbuster drug. Yet, while you may be thinking abo
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
06:15am, Friday, 14'th Jun 2024
Novo Nordisk and Medtronic are longtime leaders in the healthcare industry. Both are proven innovators with attractive prospects in the years ahead.
Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug
05:50am, Friday, 14'th Jun 2024
Eli Lilly has one obesity drug that's already competing against Wegovy, with more drugs potentially on the way. Novo Nordisk could have a more powerful obesity drug than Wegovy waiting in the wings.
3 Stocks to Buy as Ozempic Surges in Popularity
06:15am, Thursday, 13'th Jun 2024
Ozempic and Wegovy (semaglutide for diabetes and weight loss, respectively) are popular weight-loss drugs that have taken the world by storm. Indeed, the craze is showing no signs of slowing down as m
